Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus chemotherapy versus physician's choice in unresectable epithelioid pleural mesothelioma
ACTRN12620001199909Phase 3Completed
- Sponsor
- University of Sydney
- Start
- Feb 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of durvalumab in pleural mesothelioma (3 arms), sponsored by University of Sydney. Primary endpoint: Overall survival. Started Feb 2021; status: completed.
02
Drugs
durvalumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on ACTRN12620001199909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001199909.